Edwards Lifesciences (EW) Outlines Growth Strategy

Go back to Edwards Lifesciences (EW) Outlines Growth Strategy

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

December 4, 2024 6:00 AM UTC

NEW YORK--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) will discuss the companys focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), the continued long-term performance of Surgical, and future opportunities with Structural Heart Failure and Aortic Regurgitation (AR).

Highlights of todays... More